Zheng Quan Zhi Xing
Search documents
亨通光电: 亨通光电关于召开2025年半年度业绩说明会的提示性公告
Zheng Quan Zhi Xing· 2025-09-05 09:16
Core Points - The company will hold a half-year performance briefing on September 12, 2025, from 15:00 to 16:00 [1][2] - The briefing will be conducted online through "Value Online" platform [1][2] - Investors can submit questions before the briefing until September 11, 2025, at 17:00 [1][2] Meeting Details - The meeting will include participation from key company executives: Chairman Cui Wei, Independent Director Yang Junhui, General Manager Zhang Jianfeng, CFO Wu Yan, and Board Secretary Gu Yiqian [2] - Investors can engage in real-time communication during the meeting [2] - The company aims to address common investor concerns within the scope of regulatory disclosure [1][2]
海力风电: 江苏海力风电设备科技股份有限公司章程
Zheng Quan Zhi Xing· 2025-09-05 09:16
Core Points - Jiangsu Haili Wind Power Equipment Technical Co., Ltd was established as a joint-stock company in accordance with the Company Law and other relevant regulations [3][4] - The company was approved for its initial public offering of 54.348 million shares on September 22, 2021, and listed on the Shenzhen Stock Exchange on November 24, 2021 [3][4] - The registered capital of the company is RMB 217.391478 million [4] - The company's business scope includes research, production, and sales of wind power equipment components, agricultural machinery, port machinery, and environmental protection machinery [6] Company Structure - The company is governed by a board of directors, with the chairman serving as the legal representative [4][5] - The company has a permanent existence as a joint-stock company [4] - Shareholders are liable for the company's debts only to the extent of their subscribed shares, while the company is liable for its debts with all its assets [5][6] Share Issuance and Management - The company issues shares in the form of stocks, with each share having a nominal value of RMB 1 [6][8] - The total number of shares issued by the company is 217.391478 million, all of which are ordinary shares [7][8] - The company can increase its capital through various methods, including issuing shares to unspecified objects or existing shareholders [8][9] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and other benefits proportional to their shareholdings [13][14] - Shareholders are obligated to comply with laws and regulations, and they cannot withdraw their capital except as provided by law [17][18] - The company must maintain a shareholder register to document ownership and rights [13][14] Governance and Meetings - The company holds annual and extraordinary shareholder meetings, with specific procedures for calling and conducting these meetings [48][49] - Decisions at shareholder meetings require a majority or two-thirds majority vote, depending on the nature of the resolution [81][83] - The board of directors is responsible for reporting to shareholders on the company's performance and addressing shareholder inquiries [75][76]
苑东生物: 苑东生物:关于参加2025年半年度科创板创新药行业集体业绩说明会的公告
Zheng Quan Zhi Xing· 2025-09-05 09:16
Core Viewpoint - Chengdu Easton Biopharmaceutical Co., Ltd. will participate in the 2025 semi-annual performance briefing for the innovative drug industry on September 16, 2025, to enhance communication with investors regarding its operational results and financial indicators for the first half of 2025 [1][2]. Group 1: Meeting Details - The meeting is scheduled for September 16, 2025, from 15:00 to 17:00 [2]. - The location of the meeting is the Shanghai Stock Exchange Roadshow Center, accessible via the website: https://roadshow.sseinfo.com/ [2][4]. - The format of the meeting will be an online interactive session [2][4]. Group 2: Participants and Interaction - Key participants include General Manager Yuan Mingxu, Board Secretary Li Shuyun, and Chief Financial Officer Bo Xiaoqin [2]. - Investors can participate online during the meeting and submit questions in advance from September 8 to September 15, 2025, by visiting the Roadshow Center or emailing the company [2][4]. Group 3: Contact Information - For inquiries, investors can contact the Securities Department at 028-86106668 or via email at ydsw@eastonpharma.cn [3].
中船防务: 中船防务关于董事、总经理离任的公告
Zheng Quan Zhi Xing· 2025-09-05 09:16
Core Points - The resignation of Chen Liping as the company's director and general manager is due to work changes, effective September 5, 2025 [1][2] - Chen Liping's resignation does not affect the legal number of the board of directors, and the company will proceed with the election and appointment of a new director and general manager [1][2] Summary by Sections Resignation Details - Chen Liping submitted a written resignation report on September 5, 2025, resigning from the positions of director, strategic committee member, and general manager due to work changes [1] - His original term was set to expire on February 2, 2027, but he did not complete this term [1] Impact on the Company - The company confirms that Chen Liping's resignation will not impact its normal operations, and he has completed the necessary handover work [2] - Chen Liping did not hold any shares in the company and has no outstanding commitments [2] - The board expresses gratitude for Chen Liping's contributions during his tenure [2]
中船防务: 中船防务关于召开2025年半年度业绩说明会的公告
Zheng Quan Zhi Xing· 2025-09-05 09:16
证券代码:600685 证券简称:中船防务 公告编号:2025-041 中船海洋与防务装备股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ? 会议召开时间:2025 年 9 月 15 日(星期一)上午 9:00-10:00 ? 会议召开地点:上海证券交易所上证路演中心(网址: https://roadshow.sseinfo.com/) (以下简称"上证路演中心") ? 会议召开方式:上证路演中心网络互动 (一) ? 投资者可于 2025 年 9 月 8 日(星期一)至 9 月 12 日(星期五) 公司邮箱(comec@comec.cssc.net.cn)进行提问。公司将在说明会 上对投资者普遍关注的问题进行回答。 中船海洋与防务装备股份有限公司(以下简称"公司" )已于 2025 年 8 月 28 日在上海证券交易所网站(www.sse.com.cn) 、香港联合交 易所有限公司网站(www.hkexnews.hk)及公司指定信息披露媒体上 发布公司 ...
海思科: 关于向特定对象发行股票的审核问询函回复(修订稿)及募集说明书等申请文件更新的提示性公告
Zheng Quan Zhi Xing· 2025-09-05 09:16
Group 1 - The company received an inquiry letter from the Shenzhen Stock Exchange regarding its application for a specific stock issuance on July 23, 2025 [1] - The company, along with relevant intermediaries, is responding to the inquiry letter and updating the application documents, including the prospectus, with financial data as of the first half of 2025 [2] - The issuance of stocks to specific targets requires approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission, with the outcome and timing being uncertain [2]
鼎龙股份: 招商证券股份有限公司关于湖北鼎龙控股股份有限公司2025年半年度持续督导跟踪报告



Zheng Quan Zhi Xing· 2025-09-05 09:16
Group 1 - The report indicates that the sponsor, China Merchants Securities, has effectively reviewed the company's information disclosure documents and has not encountered any instances of delayed reviews [1] - The company has established and effectively executed regulations to prevent related parties from occupying company resources and to manage raised funds [1] - Monthly checks on the company's raised funds special account have been conducted, confirming that the project progress aligns with the disclosed information [1] Group 2 - The report states that there are no significant issues requiring attention from the sponsor, and no special voting rights shareholders have abused their rights [2] - The company has fulfilled its commitments, including measures to address immediate returns [2] - There are no regulatory measures or corrective actions taken against the company as per the report [2]
严牌股份: 长江证券承销保荐有限公司关于浙江严牌过滤技术股份有限公司2025半年度持续督导跟踪报告
Zheng Quan Zhi Xing· 2025-09-05 09:16
Group 1 - The report is a continuous supervision tracking report for Zhejiang Yanpai Filter Technology Co., Ltd. by Changjiang Securities [1][2] - The company has effectively established and executed relevant regulations, including those for fundraising management and internal controls [1][2] - There were two inquiries into the company's fundraising special account, and the progress of fundraising projects was consistent with disclosed information [1][2] Group 2 - The company and its shareholders have fulfilled their commitments, including extending lock-up periods and ensuring the planned use of funds [2] - There were no significant changes in the company's financial status, management, or core technology during the supervision period [2] - The report indicates that there are no major risks or issues that could affect the company's operations or contractual obligations [2]
宝新能源: 宝新能源2025年第一次临时股东大会见证法律意见书
Zheng Quan Zhi Xing· 2025-09-05 09:16
广东法制盛邦律师事务所 关于广东宝丽华新能源股份有限公司 见证法律意见书 致:广东宝丽华新能源股份有限公司 广东法制盛邦律师事务所(以下简称"本所")受广东宝丽华新能源股份有限 公司(以下简称"公司")的委托,委派本所律师出席公司 2025 年第一次临时股 东大会(以下简称"本次股东大会"),并就本次股东大会的召集和召开程序、召 集人和出席会议人员资格、表决程序、表决结果出具见证法律意见。 为出具本见证法律意见书,本所律师出席了本次股东大会,审查了公司提供 的有关本次股东大会各项议程及相关文件。在审查有关文件的过程中,公司向本 所律师保证并承诺,其向本所提交的文件和所作的说明是真实的,并已经提供出 具本见证法律意见书所必需的、真实的原始书面材料、副本材料或口头证言,有 关副本材料或复印件与原件一致。 本所律师依据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司股东会规则》及其它相关法律、法规、规范性文件、深圳证券交易所(以下 简称"深交所")规则及公司《章程》,并按照律师行业公认的业务标准、道德规 范及勤勉尽责精神,出具见证法律意见如下: 一、关于本次股东大会的召集和召开程序 本次股东大会由公司董 ...
沪硅产业: 上海硅产业集团股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易报告书(草案)(摘要)(上会稿)
Zheng Quan Zhi Xing· 2025-09-05 09:16
Core Viewpoint - Shanghai Silicon Industry Group Co., Ltd. plans to issue shares and pay cash to acquire assets while raising matching funds through a related party transaction, which involves multiple investment funds and aims to enhance its position in the semiconductor industry [1][13]. Group 1: Transaction Overview - The company intends to purchase equity stakes in three subsidiaries: Shanghai Xinxing Crystal Investment Co., Ltd. (46.7354%), Shanghai Xinxing Crystal Technology Co., Ltd. (49.1228%), and Shanghai Xinxing Crystal Rui Semiconductor Technology Co., Ltd. (various percentages) [7][13]. - The total transaction value is approximately 7.04 billion yuan, with the cash component being around 324 million yuan [16][17]. - The company will issue shares to no more than 35 specific investors to raise up to 2.1 billion yuan, which will be used for working capital and transaction-related costs [17]. Group 2: Financial and Operational Impact - The acquisition is expected to strengthen the company's capabilities in producing 300mm semiconductor wafers, enhancing its competitive edge in the semiconductor market [17][18]. - The company is recognized as one of the largest and most technologically advanced semiconductor wafer manufacturers in China, with a comprehensive product range that includes polishing wafers, epitaxial wafers, and SOI wafers [17]. - The transaction aligns with the company's strategy to cover the entire semiconductor supply chain and meet domestic customer demands across various application fields [17].